Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$44.38 USD
-0.56 (-1.25%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $44.33 -0.05 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Rhythm Pharmaceuticals, Inc. (RYTM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$56.67 | $79.00 | $42.00 | 26.10% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Rhythm Pharmaceuticals, Inc. comes to $56.67. The forecasts range from a low of $42.00 to a high of $79.00. The average price target represents an increase of 26.1% from the last closing price of $44.94.
Analyst Price Targets (9 )
Broker Rating
Rhythm Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.78% and 11.11% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RYTM.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.11 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/8/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
5/8/2024 | LadenburgThalmann | Michael Higgins | Strong Buy | Strong Buy |
4/18/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
4/10/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
1/25/2024 | Goldman Sachs | Corinne Johnson | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 9 |
Average Target Price | $56.67 |
LT Growth Rate | 19.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 68 of 252 |
Current Quarter EPS Est: | -0.70 |